Platelet Radioligand Binding and Neuroendocrine Challenge Tests in Depression

  1. Ruth Porter Organizer,
  2. Gregory Bock Organizer and
  3. Sarah Clark
  1. R. W. Horton1,
  2. C. L. E. Katona2,
  3. A. E. Theodorou1,
  4. A. S. Hale2,
  5. S. L. Davies1,
  6. C. Tunnicliffe2,
  7. Y. Yamaguchi1,
  8. E. S. Paykel2,3 and
  9. J. S. Kelly1

Published Online: 28 SEP 2007

DOI: 10.1002/9780470513361.ch6

Ciba Foundation Symposium 123 - Antidepressants and Receptor Function

Ciba Foundation Symposium 123 - Antidepressants and Receptor Function

How to Cite

Horton, R. W., Katona, C. L. E., Theodorou, A. E., Hale, A. S., Davies, S. L., Tunnicliffe, C., Yamaguchi, Y., Paykel, E. S. and Kelly, J. S. (2007) Platelet Radioligand Binding and Neuroendocrine Challenge Tests in Depression, in Ciba Foundation Symposium 123 - Antidepressants and Receptor Function (eds R. Porter, G. Bock and S. Clark), John Wiley & Sons, Ltd., Chichester, UK. doi: 10.1002/9780470513361.ch6

Author Information

  1. 1

    Department of Pharmacology and Clinical Pharmacology, St George's Hospital Medical School, Cranmer Terrace, London SW17 0RE, UK

  2. 2

    Department of Psychiatry, St George's Hospital Medical School, Cranmer Terrace, London SW17 0RE, UK

  3. 3

    Department of Psychiatry, University of Cambridge, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ, UK

Publication History

  1. Published Online: 28 SEP 2007

ISBN Information

Print ISBN: 9780471910893

Online ISBN: 9780470513361

SEARCH

Keywords:

  • platelet radioligand binding;
  • neuroendocrine challenge tests;
  • depression;
  • growth hormone response;
  • dexamethasone

Summary

The purpose of this work was to examine the number and function of α2-adrenoceptors and the number of serotonin uptake sites in depressed patients and controls. Platelet α2-adrenoceptors and platelet serotonin uptake sites were labelled with [3H]yohimbine and [3H]imipramine respectively. Central α2-adrenoceptor function was assessed by growth hormone and other responses to challenge with the α2-agonist clonidine. No overall difference in the binding parameters was observed between the control and depressed groups, but the results highlight the importance of drug-free interval, menopausal status and membrane protein concentration within the binding assays in the interpretation of such studies. The growth hormone response to clonidine tended to be blunted in depressed females and was significantly blunted in the subgroup of depressives who failed to suppress plasma cortisol concentrations in response to dexamethasone. Depressed subjects also showed a smaller decrease in diastolic blood pressure and a smaller increase in sedation than control subjects.